Precigen reports second quarter and first half 2023 financial results and provides update on portfolio prioritization and capital allocation strategies to extend projected cash runway into 2025

–   the fda confirmed that the ongoing phase 1/2 single arm study of prgn-2012 in rrp will serve as the pivotal study to support accelerated approval and no additional randomized, placebo-controlled trial will be required to support submission of a bla – –   company to prioritize portfolio activities to accelerate prgn-2012 and continue advancement of other key programs, by implementing strategies to reduce clinical costs (e.g., reducing cro costs without internal r&d headcount reduction) and reduce sg&a costs – –   completely retired the outstanding balance of convertible notes – –   cash, cash equivalents, short-term and long-term investments totaled $95.6 million as of june 30, 2023; cash runway projected into 2025 – germantown, md.
PGEN Ratings Summary
PGEN Quant Ranking